GleamWall
中文EN

BDRX Biodexa Pharmaceuticals Plc IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1643918 · Reporting currency GBP · Fiscal year ends 12/31

Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-45.5%
TTM net income YoY7.5%
TTM EPS YoY98.7%
Revenue 3-yr CAGR3.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,103.4%
Net margin-1,858.0%
FCF margin-1,798.4%
EBITDA margin—

Returns

ROE-180.6%
ROA-88.1%
ROIC (approx.)-10,464.6%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets55.6%
Debt / equity0.10x
Current ratio1.26x
Interest coverage-195.46x

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-3.1%
Payout ratio—
Capex / revenue6.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: GBP FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue——
R&D expense3.96M5.44M
Operating income-8.64M-9.20M
Interest expense229,000165,000
Pretax income-6.49M-5.98M
Income tax-105,000-250,000
Net income-6.38M-5.73M
EPS (basic)-0.00-0.00
EPS (diluted)-0.00-0.00
Balance sheet
Cash & equivalents8.53M1.67M
Receivables3.79M6.57M
Current assets12.44M8.81M
PP&E, netmay include right-of-use assets (IFRS)91,000324,000
Total assets18.18M14.78M
Current liabilities6.13M5.03M
Short-term debt61,000609,000
Long-term debt—118,000
Total debt—727,000
Total liabilities6.77M6.46M
Shareholders' equity11.40M8.32M
Net debt—-942,000
Cash flow statement
Operating cash flow-5.59M-12.26M
Capital expenditure2,0009,000
Free cash flow-5.59M-12.27M
Investing cash flow-583,000-598,000
Financing cash flow13.04M8.56M
Stock-based compensation170,000283,000

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, GBP, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.